Skip to content

RECURSION PHARMACEUTICALS, INC.

RXRX

CIK 0001601830 · Biological Products, (No Diagnostic Substances) · Nasdaq

  • Recursion Pharmaceuticals, LLC (until 2015-12-04)
← back to feed
Revenue (TTM)
$45.62M
+26.9% YoY Q1 Mar 2026
Net Income (TTM)
−$654.14M
−39.1% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$1.49
+14.8% YoY Q1 Mar 2026
Gross Margin
-51.6%
Q1 Mar 2026
Operating Margin
-1,465.1%
Q1 Mar 2026
Net Margin
-1,434.0%
Q1 Mar 2026
Free Cash Flow (TTM)
−$402.59M
Q1 Mar 2026
Cash
$654.47M
Q1 Mar 2026
Total Debt
$723K
Q1 Mar 2026
Shares Outstanding
168.32M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings